Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Google Secures Pentagon AI Deal for Classified Projects 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
SANTA MONICA, Calif., Feb. 16, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference.
| Event: | 2016 RBC Capital Markets Global Healthcare Conference | |
| Date: | Tuesday, February 23, 2016 | |
| Time: | 4:05 PM Eastern Time | |
| Location: | New York, NY | |
A live audio webcast will be available on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
